<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vniigis</journal-id><journal-title-group><journal-title xml:lang="ru">Российский паразитологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Parasitology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-8435</issn><issn pub-type="epub">2541-7843</issn><publisher><publisher-name>ВНИИП – филиал ФГБНУ ФНЦ ВИЭВ РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31016/1998-8435-2022-16-4-421-431</article-id><article-id custom-type="elpub" pub-id-type="custom">vniigis-968</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОЛОГИЯ, ТОКСИКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOLOGY, TOXICOLOGY</subject></subj-group></article-categories><title-group><article-title>Токсикологические параметры препарата на основе орнидазола и левамизола гидрохлорида</article-title><trans-title-group xml:lang="en"><trans-title>Toxicological parameters of the drug based on Ornidazole and Levamisole hydrochloride</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6045-3106</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бутенко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Butenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бутенко Александр Вячеславович, аспирант</p><p>355017, г. Ставрополь, пер. Зоотехнический, 12</p></bio><bio xml:lang="en"><p>Butenko Alexander V., graduate student</p><p>12 Zootekhnichesky per., 355017, Stavropol</p></bio><email xlink:type="simple">butenkoo.aleksandr@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4774-263X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Оробец</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Orobets</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оробец Владимир Александрович, доктор ветеринарных наук, профессор</p><p>355017, г. Ставрополь, пер. Зоотехнический, 12</p></bio><bio xml:lang="en"><p>Orobets Vladimir A., Dr. Sc. Vet., Professor</p><p>12 Zootekhnichesky per., 355017, Stavropol</p></bio><email xlink:type="simple">orobets@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9372-4400</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Киреев</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kireev</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Киреев Иван Валентинович, доктор биологических наук, профессор</p><p>355017, г. Ставрополь, пер. Зоотехнический, 12</p></bio><bio xml:lang="en"><p>Kireev Ivan V., Dr. Sc. Biol., Professor</p><p>12 Zootekhnichesky per., 355017, Stavropol</p></bio><email xlink:type="simple">kireev-iv@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ставропольский государственный аграрный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Agrarian University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>02</day><month>01</month><year>2023</year></pub-date><volume>16</volume><issue>4</issue><fpage>421</fpage><lpage>431</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Бутенко А.В., Оробец В.А., Киреев И.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Бутенко А.В., Оробец В.А., Киреев И.В.</copyright-holder><copyright-holder xml:lang="en">Butenko A.V., Orobets V.A., Kireev I.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vniigis.elpub.ru/jour/article/view/968">https://vniigis.elpub.ru/jour/article/view/968</self-uri><abstract><p>Цель исследований – изучение фармако-токсикологических свойств препарата на основе орнидазола и левамизола гидрохлорида.Материалы и методы. Изучение фармако-токсикологических свойств препарата на основе орнидазола и левамизола гидрохлорида проводили на базе лаборатории доклинических исследований факультета ветеринарной медицины Ставропольского государственного аграрного университета. Острую и хроническую токсичность, раздражающее действие препарата изучали согласно «Руководству по проведению доклинических исследований лекарственных средств» (2012). Гематологические исследования лабораторных животных выполняли при помощи автоматического гематологического анализатора, биохимические исследования сыворотки крови – при помощи автоматического биохимического анализатора.Результаты и обсуждение. Установлено, что препарат на основе орнидазола и левамизола гидрохлорида по среднесмертельной пероральной дозе в соответствии с ГОСТ 12.1.007–76 относится к третьему классу опасности - вещества умеренно опасные; не обладает выраженной субхронической токсичностью и раздражающим действием. Многократное применение действующего вещества в течение 14 сут не вызывает достоверных изменений в клиническом состоянии, гематологическом и биохимическом профиле лабораторных животных.</p></abstract><trans-abstract xml:lang="en"><p>The purpose of the research is the study of pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug.Materials and methods. The pharmaco-toxicological properties of the Ornidazole- and Levamisole hydrochloride-based drug were studied in the premises of the Laboratory of Preclinical Studies, Faculty of Veterinary Medicine, Stavropol State Agrarian University. Acute and chronic toxicity, and irritant effect of the drug was studied under the Guidelines for Preclinical Studies of Drugs (2012). Hematological studies of laboratory animals were performed with an automatic hematological analyzer, and biochemical studies of the blood serum were done with an automatic biochemical analyzer.Results and discussion. It has been found that the Ornidazole- and Levamisole hydrochloride-based drug belongs to the Hazard Class 3 for the median lethal oral dose in accordance with GOST 12.1.007–76 as moderately hazardous substances; it does not have a pronounced subchronic toxicity or irritant effect. Multiple use of the active substance for 14 days does not cause significant changes in the clinical condition, or in hematological and biochemical profile of laboratory animals.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>орнидазол</kwd><kwd>левамизол гидрохлорид</kwd><kwd>острая токсичность</kwd><kwd>субхроническая токсичность</kwd><kwd>раздражающее действие</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Ornidazole</kwd><kwd>Levamisole hydrochloride</kwd><kwd>acute toxicity</kwd><kwd>subchronic toxicity</kwd><kwd>irritant effect</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arguello-Garcia R., Leitsch D., Skinner-Adams T., Ortega-Pierres M. G. Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis. Adv. Parasitol. 2020; 107: 201-282.</mixed-citation><mixed-citation xml:lang="en">Arguello-Garcia R., Leitsch D., Skinner-Adams T., Ortega-Pierres M. G. Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis. Adv. Parasitol. 2020; 107: 201-282.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Canete R., Noda A. L., Rodriguez M. et al. 5-Nitroimidazole refractory giardiasis is common in Matanzas, Cuba and effectively treated by secnidazole plus high-do.se mebendazole or quinacrine: a prospective observational cohort study. Clin. Microbiol. Infect. 2019; 26 (8): 1092.е1-1092.е6.</mixed-citation><mixed-citation xml:lang="en">Canete R., Noda A. L., Rodriguez M. et al. 5-Nitroimidazole refractory giardiasis is common in Matanzas, Cuba and effectively treated by secnidazole plus high-do.se mebendazole or quinacrine: a prospective observational cohort study. Clin. Microbiol. Infect. 2019; 26 (8): 1092.е1-1092.е6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dobo B. Prevalence of intestinal protozoan infection among patients in Hawassa city administration millennium health center, Ethiopia. J. Appl. Biotechnol. Bioeng. 2018; 5 (4): 210-241. doi: 10.15406/jabb.2018.05.00139</mixed-citation><mixed-citation xml:lang="en">Dobo B. Prevalence of intestinal protozoan infection among patients in Hawassa city administration millennium health center, Ethiopia. J. Appl. Biotechnol. Bioeng. 2018; 5 (4): 210-241. doi: 10.15406/jabb.2018.05.00139</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2019; 146: 1167-1178.</mixed-citation><mixed-citation xml:lang="en">Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2019; 146: 1167-1178.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mørch K., Hanevik K. Giardiasis treatment: an update with a focus on refractory disease. Curr. Opin. Inf. Dis. 2020; 33 (5): 355-364. doi: 10.1097/QCO.0000000000000668</mixed-citation><mixed-citation xml:lang="en">Mørch K., Hanevik K. Giardiasis treatment: an update with a focus on refractory disease. Curr. Opin. Inf. Dis. 2020; 33 (5): 355-364. doi: 10.1097/QCO.0000000000000668</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">National Center for Biotechnology Information. PubChem Compound Summary for CID 28061, Ornidazole. https://pubchem.ncbi.nlm.nih.gov/compound/Ornidazole. Accessed Jan. 29, 2022.</mixed-citation><mixed-citation xml:lang="en">National Center for Biotechnology Information. PubChem Compound Summary for CID 28061, Ornidazole. https://pubchem.ncbi.nlm.nih.gov/compound/Ornidazole. Accessed Jan. 29, 2022.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">National Center for Biotechnology Information. PubChem Compound Summary for CID 26879, Levamisole. Retrieved January 30, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Levamisole.</mixed-citation><mixed-citation xml:lang="en">National Center for Biotechnology Information. PubChem Compound Summary for CID 26879, Levamisole. Retrieved January 30, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Levamisole.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
